These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 22363960)

  • 1. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 3. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 4. The National Childhood Vaccine Injury Act and the supreme court's interpretation.
    Blake V
    Virtual Mentor; 2012 Jan; 14(1):31-4. PubMed ID: 23116914
    [No Abstract]   [Full Text] [Related]  

  • 5. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
    Mottes LM
    Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
    [No Abstract]   [Full Text] [Related]  

  • 7. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of Wyeth v. Levine on FDA regulation of prescription drugs.
    Ausness RC
    Food Drug Law J; 2010; 65(2):247-83, i-ii. PubMed ID: 24475542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 10. Why doctors should worry about preemption.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
    [No Abstract]   [Full Text] [Related]  

  • 11. Preemption of the "fraud on the FDA" exception to Michigan's tort immunity statute for drug manufacturers: reconsidering Garcia and Desiano after Levine.
    Murdey J
    Food Drug Law J; 2011; 66(1):85-104, ii-iii. PubMed ID: 24505848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 14. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buckman extended: federal preemption of state fraud-on-the-FDA statutes.
    Gaddis CA
    Food Drug Law J; 2014; 69(1):113-36, iii. PubMed ID: 24772688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Life after Riegel: a fresh look at medical device preemption one year after Riegel v. Medtronic, Inc.
    Wartman GJ
    Food Drug Law J; 2009; 64(2):291-311. PubMed ID: 19999286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FDA, preemption, and the Supreme Court.
    Glantz LH; Annas GJ
    N Engl J Med; 2008 May; 358(18):1883-5. PubMed ID: 18450601
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renovations Needed: the FDA's Floor/Ceiling Framework, Preemption, and the Opioid Epidemic.
    Abrams MR
    Mich Law Rev; 2018 Oct; 117(1):143-71. PubMed ID: 30300989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.